Semaglutide and tirzepatide are not established treatments for kidney stones. For someone who already forms stones, the most directly relevant studies are reassuring about some urine measurements, but they do not settle whether these medicines change the number of future stone attacks. That distinction matters before treating a weight-loss prescription as a stone-prevention plan. The broader GLP-1 kidney-disease evidence answers another question.
The 44-person study: lower oxalate, unchanged supersaturation
A retrospective study followed 44 people with obesity and a history of nephrolithiasis, the medical term for kidney stones, during GLP-1-based weight-loss treatment. Participants had urine collections before and during therapy. Over a median 1.1 years, average weight declined by 6.6 kg. Urinary oxalate fell from 40 to 32 mg per day, sulfate from 21 to 17 mmol per day, and ammonium from 35 to 29 mEq per day.[1]
Those findings describe selected components of a 24-hour urine collection. They are relevant because stones form in a chemical environment, rather than from a single blood-test result. However, calcium oxalate, calcium phosphate, and uric acid supersaturation indices did not change significantly. Neither did several other measurements, including urine calcium, citrate, pH, or total urine volume. The complete result is more modest than a headline saying the medicines reduce stone risk.
The investigators did not randomize patients to a GLP-1 medicine or a control treatment. Dietary changes, weight reduction, and other aspects of care could have contributed. A sample of 44 also cannot reliably characterize rare harms or tell whether one GLP-1 drug is preferable to another. The useful conclusion is that these patients did not develop a clear worsening of the measured stone-forming urine profile during treatment. It is not a demonstrated reduction in recurrent stones.
A larger urine study did not find a GLP-1 advantage
A separate retrospective study connected Medicare prescription claims to laboratory urine collections. Its cross-sectional GLP-1 analysis compared 349 users with 349 matched controls. There were no significant differences in urine parameters in that comparison. A longitudinal analysis of 154 GLP-1 users also did not identify significant changes in urinary parameters.[2]
That paper also examined SGLT2 inhibitors, a different drug class. Some favorable cross-sectional urine findings belonged to those medicines, including higher urine citrate and volume. They must not be attributed to GLP-1 drugs because the treatments appeared in the same publication. In the longitudinal analyses, significant urinary differences were not established for either class. A reader comparing the title with the conclusion should keep each treatment and each analysis separate.
The two studies are not necessarily contradictory. They involved different populations, comparators, and measurement circumstances. A small before-and-after study can find a change in one component while a matched cross-sectional comparison finds no meaningful class-wide difference. Together they offer limited reassurance about urine chemistry, with substantial uncertainty about clinical events. Neither supplies a reliable percentage reduction in stone attacks for a person starting semaglutide.
Stone history and chronic kidney disease are different
Kidney stones are solid deposits in the urinary tract. Chronic kidney disease describes persistent impairment of kidney structure or function. A person can have either condition alone or both. A medicine that improves a kidney-disease outcome in a particular trial has not automatically been shown to prevent calcium oxalate stones. Similarly, an unchanged urine profile does not mean every other kidney safety question has been answered.
The FLOW trial explanation covers semaglutide in type 2 diabetes with chronic kidney disease. Its participants, endpoints, and clinical purpose differ from a study of recurrent stones. Claims such as “protects the kidneys” need that context. A history of one stone also does not tell a prescriber what the stone contained, whether obstruction occurred, or what prevention strategy is appropriate now.
For a consultation, the most useful history includes the type of stone if known, frequency of attacks, past procedures, previous urine testing, kidney function, and current prevention medicines. A prescriber may need records from the clinician managing recurrent stones. This is more informative than selecting a telehealth service solely because it lists kidney health among the possible benefits of weight loss.
Hydration still matters when appetite and intake fall
A GLP-1 prescription does not replace a stone-prevention plan. Nausea, vomiting, and diarrhea can interfere with fluid intake. The Wegovy prescribing information warns about acute kidney injury associated with volume depletion and recommends monitoring renal function when adverse reactions could lead to that problem.[3] This is a safety pathway to recognize, rather than proof that semaglutide directly creates kidney stones.
The practical issue is what happens during an uncomfortable treatment week: whether the person can drink, whether fluid losses are continuing, and whether there are symptoms needing assessment. The dehydration guide explains this distinction. Someone with a clinician-imposed fluid restriction should not adopt a generic internet fluid target; the appropriate plan depends on the underlying condition and the care team’s advice.
There is also no reason to assume a protein target suitable for an otherwise healthy weight-loss patient is suitable for every recurrent stone former. Existing stone advice may depend on urine findings and stone composition. Ask how any new eating plan fits the established prevention plan rather than discarding that plan because weight is falling. The protein and diet article provides general context, not a substitute for a stone-specific prescription.
Symptoms that should not be dismissed as routine side effects
Kidney stones can cause sharp back, side, lower abdominal, or groin pain; blood in the urine; painful urination; or difficulty passing urine. Fever and chills can accompany a concerning presentation. NIDDK advises prompt professional assessment for stone symptoms because another serious condition may be responsible.[4] A new urinary symptom should not be relabeled as ordinary nausea or constipation just because treatment recently started.
A person reporting severe pain plus vomiting needs an assessment of the whole picture. The location of pain, urinary changes, ability to drink, and fever all help determine the next step. A message describing “stomach upset” leaves out details that may matter. The abdominal-pain guide explains why persistent or severe symptoms deserve their own evaluation.
Do not use a quiet week without symptoms as evidence that a stone has dissolved. The urine studies did not establish stone dissolution, and weight change on a home scale cannot establish it either. Whether imaging or repeat urine testing is useful is a clinical decision based on the prior stone history, current symptoms, and treatment plan.
What a provider comparison should establish
For a buyer with recurrent stones, price is only one part of suitability. Before subscribing, establish whether the clinician can review relevant records, arrange appropriate testing, and coordinate care if symptoms or fluid losses develop. Ask whether an abnormal result can be managed through the service or requires another clinician. The telehealth intake guide describes the information a useful assessment gathers.
Pharmacy and formulation also matter. These studies do not verify the contents, concentration, or sterility of a particular seller’s vial. Compounded drugs are not FDA-approved and are not reviewed by the FDA for safety, efficacy or quality before dispensing. A provider cannot establish that its compounded product prevents stones by pointing to a urine study of a drug class. The compounded-versus-brand comparison explains the evidence boundary.
The decision to use a GLP-1 medicine can still be reasonable for an eligible patient with a stone history. The basis should be the individual indication, risks, and follow-up arrangements. The strongest stone-specific statement the present urine data support is narrower: no consistent worsening of measured stone-risk chemistry was demonstrated in these observational cohorts. Proven prevention of future attacks requires evidence that measures those attacks directly.
Reading a urine result without overinterpreting it
A 24-hour urine collection is a snapshot assembled over a day, not a prediction with certainty. The result depends on what was collected and the conditions around collection. Comparisons are most useful when the clinician can interpret them alongside prior tests, stone composition, medicines, and the patient’s recent diet. One changed number should not be taken out of that context to justify a new drug or cancel an existing prevention medicine.
It is particularly important to distinguish a statistical result from a treatment decision. A nonsignificant change means the study did not establish a difference under its analysis; it does not prove that no individual can experience a change. Likewise, a statistically significant reduction in oxalate does not establish how many painful stone episodes were avoided. The patient-centered endpoint is a future attack, procedure, obstruction, or hospitalization, and the studies discussed here did not resolve that question.
For follow-up, ask which outcome the clinician intends to track: symptoms, kidney function, urine chemistry, weight, or another measure. Each has a purpose. Clear expectations make it easier to recognize when a reassuring weight trend coexists with a separate problem requiring attention.